← News

Project Optimus and the case for early exposure-response

Project Optimus has moved dose optimization from a late-stage afterthought to an early-development expectation.

The FDA's Project Optimus has moved dose optimization in oncology from a late-stage afterthought to an early-development expectation.

For many programs that means an exposure-response analysis built while Phase 1 and 2 data are still arriving, rather than after. See the Phase 3 dose selection package.

Is this question in front of your program?

A 15-minute call is enough to tell whether modeling can move it. A fixed proposal follows within 48 hours.